DIPROMON

Multimodular biomarker analysis workflow for Diagnosis, PROgnosis and MONitoring of drug treatment response in bladder cancer (http://www.surrey.ac.uk/dipromon/index.htm)

The DIPROMON platform will allow design of a novel patient stratification concept, building the tools, technologies and procedures to apply this concept to the bladder cancer patient scenario. The final stage will be validating the concept in patients with bladder cancer.

The role of LIONEX in Dirpomon is to discover, characterise and produce purified biomarkers for test development. 

1 (Co-ordinator)
University of Surrey
SURREY
UK

Prof Hardev Pandha  h.pandha@surrey.ac.uk

2
Emergentec biodevelopment GmbH
EMTEC
Austria

Bernd Mayer  bernd.mayer@emergentec.com

3
AXO Science SAS
AXO
France

Dr Christophe Marquette  christophe.marquette@axoscience.com

4
Lionex GmbH
LIO
Germany

Mahavir Singh  info@lionex.de

5
Austrian Institute of Technology GmbH
AIT
Austria

Claudia Preininger  claudia.preininger@ait.ac.at

6
OnkoTec GmbH
OT
Austria

Gottfried Koehler   gottfried.koehler@onkotec.e